In an interview with BioPharma BoardRoom, Eric Blair, GDMC’s Chief Business Officer, discusses the company's strategic use of Series A funding to pio...
The Express Genes offering, initially launched in November 2023, now extends to larger midiprep (10μg to 100 μg) and maxiprep (100μg to 1mg) DNA p...
Tyruko® approved for all indications of reference medicine Tyruko® biosimilar to treat adults with highly active relapsing remitting multi...
The three partners are joining forces to develop drug candidates that modulate the immune response of cancer patients and block the development of metast...
The round also included premier investors such as WI Harper Group, a leading cross-border venture capital firm, and SEEDS Capital, the investment arm of go...
Travere Therapeutics, Inc. announced that it has entered into an exclusive licensing agreement with Renalys Pharma, Inc., to bring sparsentan, a dual endot...
Biocytogen’s fully human antibody sequences were generated by proprietary RenMice strains, each engineered to lack a certain drug target gene. From M...
Maureen Deehan, CEO of Vivtex, commented: “We are delighted to enter this new collaboration with Astellas Pharma. Over the past few years, Vivtex has...
Implementation of the New Guidance Could Eliminate Financial Barriers for Contraceptive Products like Twirla® for 49 Million Women These Actions Fol...
ProteinLogic extends ImmiPrint® Technology to address TB antimicrobial chemotherapy response monitoring. ProteinLogic ImmiPrint® diagnostic patt...
In a significant move, Agappe and Fujirebio have revealed plans to launch these products in June 2024. The project has already achieved significant progres...
The newly granted patent, EP3927337, which will have an effective date of February 14, 2024, and an expiry date of no earlier than 2040, is expected to cov...
As part of the agreement, Armatus will leverage Andelyn’s extensive experience in adeno-associated virus (AAV) production and its proprietary suspens...
Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patien...
© 2025 Biopharma Boardroom. All Rights Reserved.
